BR112022004986A2 - Anticorpos anti-tnfr2 e métodos de uso - Google Patents

Anticorpos anti-tnfr2 e métodos de uso

Info

Publication number
BR112022004986A2
BR112022004986A2 BR112022004986A BR112022004986A BR112022004986A2 BR 112022004986 A2 BR112022004986 A2 BR 112022004986A2 BR 112022004986 A BR112022004986 A BR 112022004986A BR 112022004986 A BR112022004986 A BR 112022004986A BR 112022004986 A2 BR112022004986 A2 BR 112022004986A2
Authority
BR
Brazil
Prior art keywords
methods
tnfr2
antibodies
tnfr2 antibodies
oncological
Prior art date
Application number
BR112022004986A
Other languages
English (en)
Inventor
L Filbert Erin
Krishnan Sushma
Tan Christine
Bahjat Rena
Yang Xiaodong
Alvarado Ryan
Original Assignee
Apexigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apexigen Inc filed Critical Apexigen Inc
Publication of BR112022004986A2 publication Critical patent/BR112022004986A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

ANTICORPOS ANTI-TNFR2 E MÉTODOS DE USO. São fornecidos anticorpos anti-receptor do fator de necrose tumoral 2 (TNFR2) e composições relacionadas, que podem ser usados em qualquer uma de uma variedade de métodos terapêuticos ou diagnósticos, incluindo o tratamento ou diagnóstico de doenças oncológicas, doenças inflamatórias e/ou autoimunes, e outras.
BR112022004986A 2019-09-17 2020-09-11 Anticorpos anti-tnfr2 e métodos de uso BR112022004986A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962901364P 2019-09-17 2019-09-17
US202062985509P 2020-03-05 2020-03-05
US202063047824P 2020-07-02 2020-07-02
US202063058016P 2020-07-29 2020-07-29
PCT/US2020/050515 WO2021055253A2 (en) 2019-09-17 2020-09-11 Anti-tnfr2 antibodies and methods of use

Publications (1)

Publication Number Publication Date
BR112022004986A2 true BR112022004986A2 (pt) 2022-09-06

Family

ID=74884556

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004986A BR112022004986A2 (pt) 2019-09-17 2020-09-11 Anticorpos anti-tnfr2 e métodos de uso

Country Status (12)

Country Link
US (1) US20220372154A1 (pt)
EP (1) EP4031177A4 (pt)
JP (1) JP2022548159A (pt)
KR (1) KR20220071214A (pt)
CN (1) CN114641311A (pt)
AU (1) AU2020348224A1 (pt)
BR (1) BR112022004986A2 (pt)
CA (1) CA3154643A1 (pt)
IL (1) IL291299A (pt)
MX (1) MX2022003249A (pt)
TW (1) TW202124415A (pt)
WO (1) WO2021055253A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022267926A1 (zh) * 2021-06-22 2022-12-29 盛禾(中国)生物制药有限公司 一种抗tnfr2抗体及其制备方法和应用
CN117858893A (zh) * 2021-06-30 2024-04-09 盛禾(中国)生物制药有限公司 一种抗tnfr2单域抗体及其制备方法和应用
AU2022308421A1 (en) * 2021-07-07 2024-01-25 Hifibio, Inc. Anti-tnfr2 antibody and uses thereof
WO2023039610A1 (en) * 2021-09-13 2023-03-16 Apexigen, Inc. Antibodies directed against sars-cov-2
CN115925929A (zh) * 2021-09-22 2023-04-07 上海康岱生物医药技术股份有限公司 抗tnfr2单克隆抗体及其应用
WO2023103962A1 (zh) * 2021-12-06 2023-06-15 三优生物医药(上海)有限公司 Tnfr2结合分子及其用途
CN116333123A (zh) * 2021-12-22 2023-06-27 宝船生物医药科技(上海)有限公司 抗tnfr2抗体及其用途
WO2023125483A1 (zh) * 2021-12-28 2023-07-06 山东先声生物制药有限公司 一种抗tnfr2抗体药物组合物
WO2023158431A1 (en) * 2022-02-18 2023-08-24 Adlai Nortye Usa Inc. Anti-tnfr2 antibody and application thereof
WO2024030888A2 (en) * 2022-08-01 2024-02-08 Yale University Tnfr2 antibodies and methods of using the same
CN116381251A (zh) * 2023-03-13 2023-07-04 广州鹏翔生物技术有限公司 一种肿瘤标志物诊断试剂盒及其诊断方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2953634B1 (en) * 2013-02-07 2021-05-26 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
AU2016263198C1 (en) * 2015-05-15 2023-10-05 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
US20190135929A1 (en) * 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
EP3374399A1 (en) * 2015-11-11 2018-09-19 Opi Vi- IP Holdco LLC Composition and methods for anti-tnfr2 antibodies
CN117903308A (zh) * 2016-05-13 2024-04-19 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
ES2941972T3 (es) * 2016-06-22 2023-05-29 Univ Paris Val De Marne Prevención o tratamiento de la recaída de neoplasias malignas hematológicas mediante un antagonista de TNFR2
AU2018268970A1 (en) * 2017-05-19 2019-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
US20200270355A1 (en) * 2017-11-09 2020-08-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides

Also Published As

Publication number Publication date
WO2021055253A2 (en) 2021-03-25
IL291299A (en) 2022-05-01
MX2022003249A (es) 2022-06-29
EP4031177A4 (en) 2023-12-06
AU2020348224A1 (en) 2022-05-12
JP2022548159A (ja) 2022-11-16
KR20220071214A (ko) 2022-05-31
WO2021055253A3 (en) 2021-04-29
US20220372154A1 (en) 2022-11-24
CA3154643A1 (en) 2021-03-25
CN114641311A (zh) 2022-06-17
EP4031177A2 (en) 2022-07-27
TW202124415A (zh) 2021-07-01

Similar Documents

Publication Publication Date Title
BR112022004986A2 (pt) Anticorpos anti-tnfr2 e métodos de uso
WO2016187220A3 (en) Anti-ror1 antibodies
CL2021003290A1 (es) Anticuerpos de unión a cd3. (divisional de solicitud 201900643)
EA201992765A1 (ru) Белки на основе антител с привитым цитокином и способы их применения в лечении рака
PH12020551261A1 (en) Il-15 conjugates and uses thereof
MX2023000781A (es) Anticuerpos monoclonales anti-cd47 humanizados, de raton, o quimericos.
CL2016000215A1 (es) Terapia y diagnóstico basado en proteínas de patología mediada por tau en enfermedad de alzheimer (divisional de sol. n° 679-14).
WO2014176128A3 (en) Compositions and methods for the therapy and diagnosis of influenza
BR122020006918B8 (pt) Anticorpo de domínio único anti-stat3 e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR112013021863A2 (pt) anticorpos anti-receptor il-6 e métodos de uso
PH12019501319A1 (en) Gremlin-1 crystal structure and inhibitory antibody
CO2020009670A2 (es) Composiciones que comprenden microbiota coseleccionada y métodos para su uso
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
MX2022001776A (es) Terapias de combinacion de inmuno oncologia con conjugados de il-2.
AU2016249140A8 (en) Anti-PACAP antibodies and uses thereof
WO2017181079A3 (en) Methods for monitoring and treating cancer
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
BR112016030774A2 (pt) anticorpo ou fragmento de ligação a antígeno do mesmo, uso de um anticorpo, métodos para redução da quantidade de protofibrilas de ?? em um indivíduo, para tratamento e/ou para profilaxia de uma doença, para medição da quantidade de protofibrilas de ?? e/ou de proteína ?? agregada em uma pessoa, e para diagnóstico de uma doença, e, composição farmacêutica
MD3768284T2 (ro) Compoziţii de entrecoccus flagellin pentru utilizare în terapie
MA39342B2 (fr) Anticorps il -21
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
MX2020012613A (es) Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones.
BR112022011570A2 (pt) Anticorpos anti-mertk e métodos de uso dos mesmos
MX2021004517A (es) Inhibidores de cinasa de janus 1 triciclicos y composiciones y metodos de los mismos.
BR112018000909A2 (pt) imunoconjugados de il22